ARWR
ARROWHEAD PHARMACEUTICALS, INC.
$74.52
+0.15%
$10.5B
No data for this timeframe.
Vol
Market Cap$10.5B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders50 funds
Inst. Value$5.6B
Inst. Activity33 buys / 17 sells
Insider Activity0B / 4S
Insider Net $-$1.8M
Recent Activity
Jun 10, 2026
short_volume
Short Volume: ARWR — 63.7% short (0.3M / 0.5M)
Short: 320,921 | Exempt: 89 | TRF Vol: 503,800 | Short Ratio: 63.7% | Off-exchange volume (dark pool
May 12, 2026
Insider
Lu Hongbo sold 2,970 shares
Director @ $76.88 ($228.3K)
Apr 23, 2026
Insider
Hamilton James C sold 10,000 shares
Chief Medical Officer @ $75.00 ($750.0K)
Apr 22, 2026
Insider
Apel Daniel Joseph sold 3,208 shares
Chief Financial Officer @ $70.11 ($224.9K)
Inst.
FRED ALGER MANAGEMENT, LLC — ADD
3,342,493 shares ($209.6M)
Inst.
Invesco Ltd. — DOUBLED
3,280,647 shares ($205.7M)
Price Targets
$88.17
+18.3% upside
Buy
Current $74.52
Low $46.00
Median $91.50
High $110.00
12 analysts
$46.00
$110.00
Analyst Ratings
4Strong Buy
13Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Market Perform → Market Perform |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 1, 2026 | JP Morgan | INITIATE | Overweight |
| Apr 21, 2026 | Morgan Stanley | UPGRADE | Equal-Weight → Overweight |
| Mar 25, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.20 ▲ +5.7% | $-1.53 — $-0.26 | 5% YoY | 11 |
| Next Q | $-1.13 ▲ +3.1% | $-1.58 — $-0.35 | -525% YoY | 11 |
| Current FY | $-3.00 ▲ +7.4% | $-3.82 — $-1.73 | -29927% YoY | 11 |
| Next FY | $-4.34 ▼ -1.5% | $-6.70 — $-1.81 | -45% YoY | 11 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $1.1B | — |
| Avoro Capital Advisors LLC | $670.9M | — |
| FMR LLC | $455.6M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $448.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | Lu Hongbo | SELL | $228.3K |
| Apr 23, 2026 | Hamilton James | SELL | $750.0K |
| Apr 22, 2026 | Apel Daniel | SELL | $224.9K |
| Mar 5, 2026 | Hamilton James | SELL | $641.9K |
50 institutional holders with $5.6B total value (88,696,745 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, Avoro. Net buying activity: 33 institutions added/increased vs 17 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 18,161,519 | $1.1B | 20.5% | — |
| 3 | Avoro Capital Advisors LLC | 10,699,999 | $670.9M | 12.1% | — |
| 4 | FMR LLC | 7,266,652 | $455.6M | 8.2% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,146,136 | $448.1M | 8.1% | — |
| 6 | STATE STREET CORP | 6,496,130 | $407.3M | 7.3% | — |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 6,032,416 | $378.2M | 6.8% | — |
| 8 | FRED ALGER MANAGEMENT, LLC | 3,342,493 | $209.6M | 3.8% | ADD +82.4% |
| 9 | Invesco Ltd. | 3,280,647 | $205.7M | 3.7% | DOUBLED +498.9% |
| 10 | BAKER BROS. ADVISORS LP | 1,992,783 | $124.9M | 2.2% | — |
| 11 | GOLDMAN SACHS GROUP INC | 1,739,923 | $109.1M | 2.0% | — |
| 12 | JANUS HENDERSON GROUP PLC | 1,436,990 | $90.1M | 1.6% | — |
| 13 | Pictet Asset Management Holding SA | 1,273,266 | $79.6M | 1.4% | — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,192,085 | $74.7M | 1.3% | — |
| 15 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,190,335 | $74.6M | 1.3% | TRIM -32.7% |
| 16 | D. E. Shaw & Co., Inc. | 1,183,838 | $74.2M | 1.3% | — |
| 17 | BANK OF AMERICA CORP /DE/ | 1,064,455 | $66.7M | 1.2% | ADD +71.1% |
| 18 | Hood River Capital Management LLC | 1,056,534 | $66.2M | 1.2% | NEW |
| 19 | RENAISSANCE TECHNOLOGIES LLC | 1,036,495 | $65.0M | 1.2% | NEW |
| 20 | VANGUARD FIDUCIARY TRUST CO | 965,775 | $60.6M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FRED ALGER MANAGEMENT, LLC | ADD | 1,832,997 | 3,342,493 | +82.4% | $209.6M | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 547,758 | 3,280,647 | +498.9% | $205.7M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 1,769,340 | 1,190,335 | -32.7% | $74.6M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 622,029 | 1,064,455 | +71.1% | $66.7M | 2026-Q1 |
| Hood River Capital Management LLC | NEW | — | 1,056,534 | — | $66.2M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 1,036,495 | — | $65.0M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 1,476,005 | 960,507 | -34.9% | $60.2M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 663,262 | 836,981 | +26.2% | $52.5M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 422,731 | 656,129 | +55.2% | $41.1M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 147,412 | 608,531 | +312.8% | $38.1M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 2,087,953 | 587,125 | -71.9% | $36.8M | 2026-Q1 |
| Nuveen, LLC | ADD | 288,578 | 499,837 | +73.2% | $31.3M | 2026-Q1 |
| Alyeska Investment Group, L.P. | ADD | 375,371 | 472,870 | +26.0% | $29.6M | 2026-Q1 |
| FRANKLIN RESOURCES INC | DOUBLED | 107,366 | 462,707 | +331.0% | $29.0M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 35,955 | 461,193 | +1182.7% | $28.9M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | DOUBLED | 28,600 | 325,700 | +1038.8% | $20.4M | 2026-Q1 |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | NEW | — | 257,133 | — | $16.1M | 2026-Q1 |
| Legal & General Group Plc | TRIM | 395,311 | 229,097 | -42.0% | $14.4M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 376,216 | 206,412 | -45.1% | $12.9M | 2026-Q1 |
| Neuberger Berman Group LLC | DOUBLED | 100,385 | 203,914 | +103.1% | $12.8M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 112,279 | 203,220 | +81.0% | $12.7M | 2026-Q1 |
| Woodline Partners LP | TRIM | 400,184 | 200,184 | -50.0% | $12.6M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 257,477 | 191,054 | -25.8% | $12.0M | 2026-Q1 |
| MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | DOUBLED | 15,802 | 184,304 | +1066.3% | $11.6M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 123,855 | 179,573 | +45.0% | $11.3M | 2026-Q1 |
3 unique insiders with 4 transactions. Net insider value: -$1.8M ($0.00 bought, $1.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | Lu Hongbo | Director | SELL | 2,970 | $76.88 | $228.3K |
| Apr 23, 2026 | Hamilton James C | Chief Medical Officer | SELL | 10,000 | $75.00 | $750.0K |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | SELL | 3,208 | $70.11 | $224.9K |
| Mar 5, 2026 | Hamilton James C | Chief Medical Officer | SELL | 10,000 | $64.19 | $641.9K |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (85% buy). Based on 20 analysts: 4 strong buy, 13 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$88.17 mean target
+18.3% upside
Buy (1.62)
$46.00 Low
$110.00 High
| Metric | Value |
|---|---|
| Current Price | $74.52 |
| Target Low | $46.00 |
| Target Mean | $88.17 |
| Target Median | $91.50 |
| Target High | $110.00 |
| # Analysts | 12 |
| Recommendation | Buy (1.62) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.20 | $-1.53 | $-0.26 | 4.6% | +5.7% | 7↑ 2↓ | $0.0B | 68.1% | 11 |
| Next Q 2026-09-30 |
$-1.13 | $-1.58 | $-0.35 | -525.3% | +3.1% | 4↑ 3↓ | $0.1B | -69.3% | 11 |
| Current FY 2026-09-30 |
$-3.00 | $-3.82 | $-1.73 | -29927.3% | +7.4% | 7↑ 3↓ | $0.4B | -46.5% | 11 |
| Next FY 2027-09-30 |
$-4.34 | $-6.70 | $-1.81 | -44.5% | -1.5% | 4↑ 5↓ | $0.3B | -24.2% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.202 | |
| 7d ago | $-1.202 | -0.000 |
| 30d ago | $-1.274 | +0.072 |
| 60d ago | $-1.369 | +0.167 |
| 90d ago | $-1.369 | +0.167 |
9 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 1, 2026 | JP Morgan | INITIATE | — | Overweight |
| Apr 21, 2026 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Mar 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 22, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Jan 7, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Jan 7, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 7, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 13 | 3 | 0 | 0 | 85% | |
| May 1, 2026 | 4 | 12 | 3 | 0 | 0 | 84% | |
| Apr 1, 2026 | 4 | 11 | 4 | 0 | 0 | 79% | |
| Mar 1, 2026 | 4 | 11 | 4 | 0 | 0 | 79% | |
| Feb 1, 2026 | 4 | 11 | 5 | 0 | 0 | 75% | |
| Jan 1, 2026 | 4 | 11 | 5 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 10, 2026
short_volume
Short Volume: ARWR — 63.7% short (0.3M / 0.5M)
Short: 320,921 | Exempt: 89 | TRF Vol: 503,800 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: ARWR — 59.7% short (0.3M / 0.6M)
Short: 334,615 | Exempt: 2,753 | TRF Vol: 560,293 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
Clinical Trial
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
Phase Phase 3 — COMPLETED
Jun 3, 2026
short_volume
Short Volume: ARWR — 55.4% short (0.3M / 0.5M)
Short: 299,984 | Exempt: 35 | TRF Vol: 541,184 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: ARWR — 65.4% short (0.5M / 0.7M)
Short: 462,252 | Exempt: 0 | TRF Vol: 707,120 | Short Ratio: 65.4% | Off-exchange volume (dark pool + OTC)
May 30, 2026
Clinical Trial
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
Phase Phase 2 — COMPLETED
May 27, 2026
short_volume
Short Volume: ARWR — 76.3% short (0.4M / 0.6M)
Short: 432,855 | Exempt: 0 | TRF Vol: 567,677 | Short Ratio: 76.3% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: ARWR — 75.3% short (0.5M / 0.6M)
Short: 458,781 | Exempt: 0 | TRF Vol: 609,261 | Short Ratio: 75.3% | Off-exchange volume (dark pool + OTC)
May 23, 2026
Clinical Trial
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
Phase Phase 2 — TERMINATED
May 21, 2026
short_volume
Short Volume: ARWR — 57.8% short (0.4M / 0.7M)
Short: 419,619 | Exempt: 605 | TRF Vol: 726,365 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: ARWR — 84.5% short (0.5M / 0.6M)
Short: 467,291 | Exempt: 0 | TRF Vol: 552,865 | Short Ratio: 84.5% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: ARWR — 80.0% short (0.7M / 0.9M)
Short: 735,786 | Exempt: 209 | TRF Vol: 919,844 | Short Ratio: 80.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: ARWR — 79.5% short (0.5M / 0.6M)
Short: 492,783 | Exempt: 733 | TRF Vol: 619,670 | Short Ratio: 79.5% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ARWR — 73.7% short (0.4M / 0.6M)
Short: 446,659 | Exempt: 228 | TRF Vol: 605,688 | Short Ratio: 73.7% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: ARWR — 69.8% short (0.4M / 0.6M)
Short: 439,055 | Exempt: 330 | TRF Vol: 629,055 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
May 13, 2026
Clinical Trial
Study of ARO-APOC3 in Adults With Dyslipidemia
Phase Phase 2 — COMPLETED
May 13, 2026
short_volume
Short Volume: ARWR — 77.4% short (0.5M / 0.6M)
Short: 485,040 | Exempt: 598 | TRF Vol: 626,337 | Short Ratio: 77.4% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: ARWR — 74.3% short (0.5M / 0.6M)
Short: 482,346 | Exempt: 908 | TRF Vol: 648,844 | Short Ratio: 74.3% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: ARWR — 62.3% short (0.6M / 0.9M)
Short: 561,250 | Exempt: 128 | TRF Vol: 901,559 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
Clinical Trial
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Phase Phase 2 — COMPLETED